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OBJECTIVES: To understand real world persistence in patients receiving goli-
mumab, adalimumab and etanercept for treatment of rheumatoid arthritis (RA),
psoriatic arthritis (PsA), and ankylosing spondylitis (AS) using administrative
claims data.METHODS: This study used theMarketScan® Research Database from
Thomson Reuters. Patients were diagnosedwith RA, PsA, or AS and aged18 years
at index date, with continuous enrollment for 6 months prior to and 364 days
following the initial medication fill. Patients had 2 fills and a 28-31 day supply of
study drug (golimumab, adalimumab, or etanercept) for all fills during the 365 day
study period. Patients were matched using propensity score matching for demo-
graphic characteristics, and 1:1 matching for prior biologic experience. Duration of
therapy was calculated as date of last dose within the study windowminus date of
first dose plus the days supply for the last dose. Treatment persistencewas defined
as the percentage of time a patientwas on therapy during the 365-day study period.
RESULTS: Prior to matching, there were significant differences between the goli-
mumab, adalimumab, and etanercept cohorts in age, gender, geographic region,
previous biologic use, last biologic previous to index biologic, primary diagnosis,
and psoriasis comorbidity. In the matched cohorts, no significant differences were
found in duration of therapy between the golimumab (259.73 days; 95% CI: 247.20-
272.26) and adalimumab (268.75 days; 95%CI: 256.03-281.47) patients or persistence
(71.16% [95%CI: 67.73%-74.59%] vs. 73.63% [95%CI: 70.16%-77.10%]). Likewise, there
were no significant differences in duration of therapy (267.82 [95% CI: 253.81-
281.83] vs. 276.26 days [95% CI: 261.68-290.84]) or persistence (73.38% [95% CI: 69.54-
77.22] vs. 75.69% [95% CI: 72.59-78.79]) between the golimumab and etanercept
cohorts. CONCLUSIONS: The mean treatment persistence among golimumab pa-
tients is over 70%, and when matched to patients taking adalimumab or etaner-
cept, both duration of therapy and persistence are numerically equivalent.
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OBJECTIVES: This study reports dosing and refill compliance observed in goli-
mumab (GLM)-treated psoriatic arthritis (PsA) patients.METHODS: This retrospec-
tive analysis assessed GLM use in adult PsA patients with 2 GLM prescriptions
between April 24, 2009 and December 31, 2010;  1 PsA diagnosis during the study
period; continuous activity in the Source® LX database (6 months before; 6
months after the index GLM prescription); and a 28-31 day GLM supply. Refill com-
pliance was defined as occurring  1 week of the expected 28-31 day (d) interval.
The percent of compliant refill intervals and the percent of patients demonstrating
refill compliance at the 6th GLM dose were assessed. Descriptive statistics were
used to express the results. RESULTS: A total of 262 PsA patients and 1,489 GLM
refill intervals were observed. The sample was 59% female; mean age of 50 years
with 72% bio-experienced. A 50 mg GLM dose was found in 97% of all fills. The
meanSD refill interval was 35.619.8 dwith amedian of 31 d. Mean refill intervals
in bio-experienced patientswere 34.918.4 d and 37.423.2 d in bio-naïve patients.
The median was 31 d in both subgroups. Refill compliance was observed in 80% of
all intervals and in 84% of patients at the 6th GLM dose (87% of bio-naïve and 82% of
bio-experienced patients). CONCLUSIONS: In this retrospective, administrative
claims analysis 97% of GLM doses were 50 mg with approximately once monthly
refill intervals. Overall refill compliance was observed in approximately 80% of all
GLM refills and in greater than 80% of PsA patients at the sixth GLM dose. Median
refill interval and refill compliance appeared similar in bio-experienced and bio-
naïve subgroups. Further study of these trends using additional data sources are
desired to substantiate these preliminary findings.
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OBJECTIVES: This study assessed sociodemographics, health characteristics, and
intentional (INA) and unintentional (UNA) non-adherence to symptom-managing
non-steroidal anti-inflammatory drugs (NSAIDs) and disease modifying antirheu-
matic drugs (DMARDs) in patients with rheumatoid arthritis (RA).METHODS: Data
from US 2011 National Health and Wellness Survey (n75,000) included 468 re-
spondents reporting RA diagnosis (including year), exclusive of other arthritis, and
currently using biologic DMARDs (n171), non-biologic DMARDs (n165), or
NSAIDs alone (n132). Morisky Medication Adherence Scale items were coded to
create INA (“stop taking medicine when feeling [better/worse]”) and UNA (“[forget
to take/careless about taking] medicine”) scores: 0adherent; 1non-adherent.
Chi-square and t tests compared INA/UNA, sociodemographics, years since diag-
nosis, adjusted Charlson comorbidity index (CCI) scores, Work Productivity and
Activity Impairment (WPAI) scores, and Short Form (SF)-12v2 health status across
treatment categories. Multinomial logistic regression predicted treatment
(referenceNSAIDs), adjusting for many variables listed above. RESULTS: NSAID
versus non-biologic/biologic DMARD users had higher INA (31.8% vs. 13.3%/15.2%,
respectively) andweremore frequently AfricanAmerican. Non-biologic DMARDvs.
NSAID and biologic users were more frequently female, with lower overall work
impairment (among n197 employed) and activity impairment (42.1% vs. 56.5%
and 51.2%). Non-biologic DMARD vs. NSAID users had lower CCI and better SF-12v2
component summary and utility scores. Biologic DMARD, vs. NSAID and non-bio-
logic users, had higher income. Regression revealed higher odds of INA in NSAID
versus non-biologic (278%) and biologic (248%) DMARD users, plus higher odds of
insurance in non-biologic (218%) and biologic (252%) users. For all results listed,
p0.05. CONCLUSIONS: NSAID versus DMARD users had higher INA, perhaps re-
flecting perceptions of symptommanagement as an occasional need. DMARD (es-
pecially biologic) users had greater socioeconomic means to access treatment.
Health status and productivity were on average best among non-biologic DMARD
users, perhaps reflecting disease-modifying treatments’ relative efficacy plus
lower disease severity in non-biologic versus biologic users.
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OBJECTIVES: Although gout has been found to be associated with health-related
quality of life (HRQoL), few studies have examined the burden of gout in the pres-
ence of concomitant cardiometabolic conditions. The present study evaluated the
effect of gout on HRQoL and work productivity among patients with hypertension.
METHODS:Data from the 2010National Health andWellness Surveywere obtained
for respondents 18 years who reported physician-diagnosed hypertension or BP
levels140/90 mmHg (130/80 mmHg for those with physician-diagnosed diabe-
tes or CKD). Bivariate analysis was used to evaluate differences between patients
with and without comorbid gout. Generalized linear models were used to evaluate
productivity (using the WPAI) and HRQoL (using the PCS, MCS, and health utilities
from the SF-12v2) differences. Because uric acid levels may influence other organ
systems, coremodeling did not include comorbidities other than osteoarthritis and
depression as covariates. Sensitivity analyses controlled for the Charlson comor-
bidity index (CCI). RESULTS:A total of 22,686 patients with hypertensionmet study
eligibility requirements. 4.51% of patients reported having gout. These patients
were older,more likely to bemale, andhave insurance through theVA (all ps0.05).
Patients with comorbid gout reported lower levels of MCS (47.25 vs. 48.93), PCS
(39.06 vs. 43.78), and health utilities (0.68 vs. 0.73, all ps0.05). For both PCS and
health utilities, differences between groups exceeded clinically-meaningful cut-
offs. Sensitivity analyses conducted on PCS and health utilities uncovered slightly
smaller, but statistically significant and clinically-meaningful, effects (ps.05). The
effect of gout on overall work impairment (23.33% vs. 17.40% with and without
comorbid gout, respectively) remained after controlling for CCI. Significantly
greater impairment in daily activities (38.96% vs. 28.32%, p0.05) was also observed
among patients with comorbid gout. CONCLUSIONS: Results demonstrate that
gout has significant and clinically-meaningful impact on work productivity, phys-
ical HRQoL and utilities independent of other health conditions.
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OBJECTIVES: Understanding the preferences of parents of children with juvenile
idiopathic arthritis (JIA) regarding effectiveness, convenience, safety, and cost of
drug treatments can improve disease management. The objective of this research
was to examine parents’ stated preferences for drug treatments and health out-
comes in JIA and identify demographic and health-related factors that have a sig-
nificant impact on preferences.METHODS: A discrete choice experiment was con-
ducted in 105 parents of children with JIA who were cared for by a rheumatologist
at The Hospital for Sick Children, Canada. Parameter estimates derived from the
pilot studywere used to generate amain study experimental designwith improved
utility balance for assessing the attributes: pain, participation in daily activities,
drug administration, side-effects, days missed from school, and cost. Multinomial
logit regression was used to estimate utilities for attribute levels and interaction
terms. RESULTS: Participation in daily activities was the most important attribute,
accounting for 38% of total utility, followed by pain (27%), and drug cost (17%).
Parents of children with longer disease durations had stronger preferences for
improved participation in daily activities compared to the sample as a whole (ad-
ditional utility per year 0.09, p0.0001) while parents of older JIA patients had
stronger preferences for improved pain control (additional utility per year 0.74,
p0.01). Parents from low income households had less preference for high cost
treatments compared to the sample as a whole (additional disutility -0.33,
p0.002). CONCLUSIONS: Parents of children with JIA demonstrated strong pref-
erences for treatments that reduce pain and improve daily functioning. Under-
standing how parents trade between attributes related to drug treatments and
health outcomes when selecting a treatment for their child could help inform
clinical practice and improve disease management. The identification of variables
that influence preference could provide direction to professionals seeking themost
appropriate treatments for JIA patients.
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